Veracyte, Inc. (VCYT)Healthcare | Diagnostics & Research | South San Francisco, United States | NasdaqGM
33.80 USD
+0.77
(2.331%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 33.80 Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:44 p.m. EDT
Veracyte presents as a 'Classic GARP' with a solid balance sheet and growing earnings, yet it is trapped in a technical bearishness that options traders have capitalized on. While the fundamentals justify a medium-term hold given the valuation uplift seen in growth (Revenue +18.5%, Earnings +7%), the option market is aggressively selling volatility (Iron Condors) and positioning bets against a deeper move to the $22-$25 floor. Until price action convincingly breaks above the 50-day average or earnings prove the downtrend correction was premature, the short-term trend remains negative, making this a neutral-to-hold position yearning for a catalyst. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.146798 |
| AutoETS | 0.148308 |
| MSTL | 0.158362 |
| AutoTheta | 0.161843 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 48% |
| H-stat | 5.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.368 |
| Excess Kurtosis | -0.92 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.028 |
| Revenue per Share | 6.581 |
| Market Cap | 2,685,694,720 |
| Trailing P/E | 41.22 |
| Forward P/E | 19.06 |
| Beta | 1.96 |
| Profit Margins | 12.83% |
| Website | https://www.veracyte.com |
As of April 18, 2026, 11:44 p.m. EDT: Options data highlights significant seller positioning. In the near term (May '26), strong Iron Condor activity is evident at the $30/$45 strikes, with $41 in OTM puts and $45 in OTM calls, reflecting a bearish skew and high premium selling to capture decay. While there is speculative "New Flow" into a May $45 call with 92 volume units, the overwhelming majority of options activity (total exp volume 43, total OI 52) at this maturity is put-based ($41 vs $11 call OI). Looking further out (June '26 and beyond), the market has placed massive leverage on downside protection via calls at $50/$55 (June) and deep in-the-money puts at $45 (Sept '26), suggesting speculators have priced in a high probability of downside deviation or failed momentum, despite the stock being below its 50-day moving average.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.10457516 |
| Address1 | 6,000 Shoreline Court |
| Address2 | Suite 300 |
| All Time High | 86.03 |
| All Time Low | 4.21 |
| Ask | 33.89 |
| Ask Size | 1 |
| Audit Risk | 2 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 728,170 |
| Average Daily Volume3 Month | 921,467 |
| Average Volume | 921,467 |
| Average Volume10Days | 728,170 |
| Beta | 1.957 |
| Bid | 33.69 |
| Bid Size | 1 |
| Board Risk | 1 |
| Book Value | 16.502 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 33.8 |
| Current Ratio | 8.148 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 34.565 |
| Day Low | 33.3 |
| Debt To Equity | 3.028 |
| Display Name | Veracyte |
| Earnings Call Timestamp End | 1,778,013,000 |
| Earnings Call Timestamp Start | 1,778,013,000 |
| Earnings Growth | 7.12 |
| Earnings Quarterly Growth | 7.048 |
| Earnings Timestamp | 1,778,011,200 |
| Earnings Timestamp End | 1,778,011,200 |
| Earnings Timestamp Start | 1,778,011,200 |
| Ebitda | 84,402,000 |
| Ebitda Margins | 0.16320999 |
| Enterprise To Ebitda | 27.398 |
| Enterprise To Revenue | 4.472 |
| Enterprise Value | 2,312,459,776 |
| Eps Current Year | 1.64899 |
| Eps Forward | 1.77346 |
| Eps Trailing Twelve Months | 0.82 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 243 6388 |
| Fifty Day Average | 33.944 |
| Fifty Day Average Change | -0.144001 |
| Fifty Day Average Change Percent | -0.004242311 |
| Fifty Two Week Change Percent | 10.457516 |
| Fifty Two Week High | 50.71 |
| Fifty Two Week High Change | -16.91 |
| Fifty Two Week High Change Percent | -0.3334648 |
| Fifty Two Week Low | 22.61 |
| Fifty Two Week Low Change | 11.189999 |
| Fifty Two Week Low Change Percent | 0.49491367 |
| Fifty Two Week Range | 22.61 - 50.71 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,383,139,800,000 |
| Float Shares | 79,017,433 |
| Forward Eps | 1.77346 |
| Forward P E | 19.058788 |
| Free Cashflow | 86,797,248 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 755 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.72165 |
| Gross Profits | 373,198,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00999 |
| Held Percent Institutions | 1.1056199 |
| Implied Shares Outstanding | 79,458,427 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. |
| Long Name | Veracyte, Inc. |
| Market | us_market |
| Market Cap | 2,685,694,720 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_42154124 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 66,353,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,689,667,753 |
| Number Of Analyst Opinions | 11 |
| Open | 34.11 |
| Operating Cashflow | 136,307,008 |
| Operating Margins | 0.17501 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 650 243 6300 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 33.8 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 33.03 |
| Price Eps Current Year | 20.497395 |
| Price Hint | 2 |
| Price To Book | 2.0482364 |
| Price To Sales Trailing12 Months | 5.1933107 |
| Profit Margins | 0.12831001 |
| Quick Ratio | 7.634 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.69231 |
| Region | US |
| Regular Market Change | 0.77 |
| Regular Market Change Percent | 2.33122 |
| Regular Market Day High | 34.565 |
| Regular Market Day Low | 33.3 |
| Regular Market Day Range | 33.3 - 34.565 |
| Regular Market Open | 34.11 |
| Regular Market Previous Close | 33.03 |
| Regular Market Price | 33.8 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,175,194 |
| Return On Assets | 0.0291 |
| Return On Equity | 0.053390004 |
| Revenue Growth | 0.185 |
| Revenue Per Share | 6.581 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 79,458,427 |
| Shares Percent Shares Out | 0.0796 |
| Shares Short | 6,325,353 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 5,491,867 |
| Short Name | Veracyte, Inc. |
| Short Percent Of Float | 0.0887 |
| Short Ratio | 5.89 |
| Source Interval | 15 |
| State | CA |
| Symbol | VCYT |
| Target High Price | 53.0 |
| Target Low Price | 37.0 |
| Target Mean Price | 46.81818 |
| Target Median Price | 48.0 |
| Total Cash | 412,888,992 |
| Total Cash Per Share | 5.196 |
| Total Debt | 39,654,000 |
| Total Revenue | 517,144,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.82 |
| Trailing P E | 41.219513 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 35.19245 |
| Two Hundred Day Average Change | -1.3924522 |
| Two Hundred Day Average Change Percent | -0.03956679 |
| Type Disp | Equity |
| Volume | 1,175,194 |
| Website | https://www.veracyte.com |
| Zip | 94,080 |